Literature DB >> 8726005

Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays.

K Venkateswarlu1, D W Denning, N J Manning, S L Kelly.   

Abstract

D0870 was 12 to 15 times more active than fluconazole in experiments to determine the MIC for growth arrest for two isolates of Candida albicans. A biochemical comparison of in vitro sterol biosynthesis in cell extracts showed only a twofold superiority of D0870 over fluconazole. A large differentiation (10-fold) in 50% saturating concentrations obtained by examining the binding of the azoles to microsomal P-450 was observed in a type II binding spectrophotometric assay, possibly reflecting the differential affinity for more than one P-450 enzyme. Additional mechanisms besides affinity for the target enzyme sterol 14 alpha-demethylase, such as differential intracellular accumulation of drug, may contribute to the differences in antifungal activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726005      PMCID: PMC163335          DOI: 10.1128/AAC.40.6.1382

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains.

Authors:  S A Howell; A I Mallet; W C Noble
Journal:  J Appl Bacteriol       Date:  1990-11

3.  Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis.

Authors:  M A McIlroy
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

4.  A novel method for studying ergosterol biosynthesis by a cell-free preparation of Aspergillus fumigatus and its inhibition by azole antifungal agents.

Authors:  S A Ballard; S W Ellis; S L Kelly; P F Troke
Journal:  J Med Vet Mycol       Date:  1990

Review 5.  Biochemical approaches to selective antifungal activity. Focus on azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; M C Coene; G Willemsens; D Bellens; I Roels; H Moereels; P A Janssen
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

Review 6.  Epidemiology of nosocomial fungal infections, with emphasis on Candida species.

Authors:  W R Jarvis
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

7.  Purification and reconstitution of activity of Saccharomyces cerevisiae P450 61, a sterol delta 22-desaturase.

Authors:  S L Kelly; D C Lamb; A J Corran; B C Baldwin; L W Parks; D E Kelly
Journal:  FEBS Lett       Date:  1995-12-18       Impact factor: 4.124

8.  Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles.

Authors:  D A Goff; S L Koletar; W J Buesching; J Barnishan; R J Fass
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

9.  In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp.

Authors:  H M Wardle; D Law; C B Moore; C Mason; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

10.  Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.

Authors:  D W Denning; L Hall; M Jackson; S Hollis
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  9 in total

1.  Anti-Candida activity of a new platinum derivative.

Authors:  T Watanabe; M Takano; A Ogasawara; T Mikami; T Kobayashi; M Watabe; T Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

3.  Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.

Authors:  Masaru Matsumoto; Kazuya Ishida; Akihiro Konagai; Kazunori Maebashi; Takemitsu Asaoka
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Characterization of Saccharomyces cerevisiae CYP51 and a CYP51 fusion protein with NADPH cytochrome P-450 oxidoreductase expressed in Escherichia coli.

Authors:  K Venkateswarlu; D E Kelly; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

5.  Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance.

Authors:  K Venkateswarlu; D W Denning; N J Manning; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo.

Authors:  Ren-Yi Lu; Ting-Jun-Hong Ni; Jing Wu; Lan Yan; Quan-Zhen Lv; Li-Ping Li; Da-Zhi Zhang; Yuan-Ying Jiang
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

7.  Mechanism of fluconazole resistance in Candida krusei.

Authors:  A S Orozco; L M Higginbotham; C A Hitchcock; T Parkinson; D Falconer; A S Ibrahim; M A Ghannoum; S G Filler
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

8.  NADPH cytochrome P-450 oxidoreductase and susceptibility to ketoconazole.

Authors:  K Venkateswarlu; D E Kelly; N J Manning; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

9.  Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance.

Authors:  Nidia Alvarez-Rueda; Audrey Fleury; Florent Morio; Fabrice Pagniez; Louis Gastinel; Patrice Le Pape
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.